No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 36 of the 40 quarters in the window, leaving 4 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 8.9x · 10Y median 18.5x · 11th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:57:29.169Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Madrigal Pharmaceuticals, Inc. (MDGL) stock was $497.13 as of Oct 6, 2026, 12:55 PM EDT, up 0.71% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +11.4% · 3-year avg +52.0%/yr · 5-year avg +44.4%/yr
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders.
Biotechnology · West Conshohocken, PA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
-0.84
Revenue Est.
$404.69M
Last Quarter Results
EPS
$-1.99
vs Estimate
$-2.23
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MDGL | $11.49B | $497.13 | +0.71% | +11.37% | +44.41% | +41.50% | N/A |
| 2TECH | $11.34B | $72.45 | -0.18% | +15.99% | -9.26% | +10.77% | vs MDGL |
| 3DVA | $11.67B | $181.72 | +1.68% | +36.06% | +9.22% | +10.80% | vs MDGL |
| 4COO | $10.97B | $56.24 | -0.93% | -19.35% | -11.35% | +2.53% | vs MDGL |
| 5BMRN | $10.87B | $56.26 | -2.23% | +3.79% | -5.59% | -4.98% | vs MDGL |
| 6UHS | $10.67B | $176.22 | +0.10% | -14.61% | +6.18% | +4.35% | vs MDGL |
forward FY estimate
N/A
$364.30M
vs Estimate
$352.13M
Consensus Rating
Based on 18 analysts
Average Price Target
$682.11
+37.2% upside
Low
$543.00
Current
$497.13
High
$962.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.68 | $-0.84 | $-0.08 | 5 |
| Quarter ending Dec 2026 | $-0.33 | $-0.12 | $0.19 | 4 |
| Quarter ending Mar 2027 | $-0.37 | $-0.34 | $-0.32 | 1 |
| Quarter ending Jun 2027 | $0.68 | $0.73 | $0.79 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-8.67 | $-6.02 | $-3.83 | 9 |
| FY 2027 | $-5.41 | $6.11 | $11.27 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $389.19M | $404.69M | $415.18M | 10 |
| Quarter ending Dec 2026 | $419.78M | $444.69M | $467.21M | 10 |
| Quarter ending Mar 2027 | $418.56M | $444.51M | $471.96M | 9 |
| Quarter ending Jun 2027 | $481.60M | $511.46M | $543.04M | 9 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.48B | $1.52B | $1.55B | 13 |
| FY 2027 | $1.90B | $2.13B | $2.31B | 12 |
